274 related articles for article (PubMed ID: 29411170)
1. The potential of antisense oligonucleotide therapies for inherited childhood lung diseases.
Martinovich KM; Shaw NC; Kicic A; Schultz A; Fletcher S; Wilton SD; Stick SM
Mol Cell Pediatr; 2018 Feb; 5(1):3. PubMed ID: 29411170
[TBL] [Abstract][Full Text] [Related]
2. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
3. Tips to Design Effective Splice-Switching Antisense Oligonucleotides for Exon Skipping and Exon Inclusion.
Maruyama R; Yokota T
Methods Mol Biol; 2018; 1828():79-90. PubMed ID: 30171536
[TBL] [Abstract][Full Text] [Related]
4. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.
Barresi V; Musmeci C; Rinaldi A; Condorelli DF
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138
[TBL] [Abstract][Full Text] [Related]
5. An Overview of Recent Advances and Clinical Applications of Exon Skipping and Splice Modulation for Muscular Dystrophy and Various Genetic Diseases.
Rodrigues M; Yokota T
Methods Mol Biol; 2018; 1828():31-55. PubMed ID: 30171533
[TBL] [Abstract][Full Text] [Related]
6. Genetic therapies for inherited neuromuscular disorders.
Scoto M; Finkel R; Mercuri E; Muntoni F
Lancet Child Adolesc Health; 2018 Aug; 2(8):600-609. PubMed ID: 30119719
[TBL] [Abstract][Full Text] [Related]
7. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.
Wilton SD; Fletcher S
Curr Gene Ther; 2011 Aug; 11(4):259-75. PubMed ID: 21453280
[TBL] [Abstract][Full Text] [Related]
8. Invention and Early History of Exon Skipping and Splice Modulation.
Lim KRQ; Yokota T
Methods Mol Biol; 2018; 1828():3-30. PubMed ID: 30171532
[TBL] [Abstract][Full Text] [Related]
9. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
10. Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switching.
Fragall CT; Adams AM; Johnsen RD; Kole R; Fletcher S; Wilton SD
BMC Med Genet; 2011 Oct; 12():141. PubMed ID: 22013876
[TBL] [Abstract][Full Text] [Related]
11. RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes.
Wilton SD; Fletcher S
Curr Gene Ther; 2005 Oct; 5(5):467-83. PubMed ID: 16250888
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy.
Echigoya Y; Lim KRQ; Trieu N; Bao B; Miskew Nichols B; Vila MC; Novak JS; Hara Y; Lee J; Touznik A; Mamchaoui K; Aoki Y; Takeda S; Nagaraju K; Mouly V; Maruyama R; Duddy W; Yokota T
Mol Ther; 2017 Nov; 25(11):2561-2572. PubMed ID: 28865998
[TBL] [Abstract][Full Text] [Related]
13. Antisense Oligonucleotide Therapeutics for Cystic Fibrosis: Recent Developments and Perspectives.
Kim YJ; Krainer AR
Mol Cells; 2023 Jan; 46(1):10-20. PubMed ID: 36697233
[TBL] [Abstract][Full Text] [Related]
14. Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy.
Aslesh T; Yokota T
Methods Mol Biol; 2020; 2176():69-85. PubMed ID: 32865783
[TBL] [Abstract][Full Text] [Related]
15. Splice-switching antisense oligonucleotides as therapeutic drugs.
Havens MA; Hastings ML
Nucleic Acids Res; 2016 Aug; 44(14):6549-63. PubMed ID: 27288447
[TBL] [Abstract][Full Text] [Related]
16. Translational development of splice-modifying antisense oligomers.
Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
[TBL] [Abstract][Full Text] [Related]
17. Injection site reactions after long-term subcutaneous delivery of drisapersen: a retrospective study.
Hilhorst N; Spanoudi-Kitrimi I; Goemans N; Morren MA
Eur J Pediatr; 2019 Feb; 178(2):253-258. PubMed ID: 30448867
[TBL] [Abstract][Full Text] [Related]
18. Recent advancements in exon-skipping therapies using antisense oligonucleotides and genome editing for the treatment of various muscular dystrophies.
Hwang J; Yokota T
Expert Rev Mol Med; 2019 Oct; 21():e5. PubMed ID: 31576784
[TBL] [Abstract][Full Text] [Related]
19. Systematic Approach to Developing Splice Modulating Antisense Oligonucleotides.
Aung-Htut MT; McIntosh CS; Ham KA; Pitout IL; Flynn LL; Greer K; Fletcher S; Wilton SD
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31614438
[TBL] [Abstract][Full Text] [Related]
20. Antisense therapies in neurological diseases.
Brunet de Courssou JB; Durr A; Adams D; Corvol JC; Mariani LL
Brain; 2022 Apr; 145(3):816-831. PubMed ID: 35286370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
